Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8155327 | 0.85 | PTGS2 (0.54) | ALDH1A1NEK1KDM4EMAPT | |
| SCHEMBL3538604 | 0.81 | CTSD (0.58) | CYP11B1CYP11B2SLC2A1ALDH1A1LMNA | |
| SCHEMBL110896 | 0.81 | ALDH1A1 (0.43) | CYP11B1CYP11B2CYP19A1SLC2A1ALDH1A1 | |
| SCHEMBL7084334 | 0.80 | CYP11B1 (0.64) | CYP11B1CYP11B2CYP19A1SLC2A1ALDH1A1 | |
| SCHEMBL8179683 | 0.79 | ALDH1A1 (0.61) | CYP11B1CYP11B2CYP19A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7569920 | 0.79 | TDP1 (0.53) | ALDH1A1LMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL112011 | 0.78 | ALOX15 (0.48) | CYP11B1CYP11B2CYP19A1SLC2A1ALDH1A1 | |
| SCHEMBL29663125 | 0.77 | CA1 (0.54) | KDM4EMAPT | |
| SCHEMBL30877906 | 0.77 | CA1 (0.54) | KDM4EMAPT | |
| SCHEMBL18355729 | 0.77 | MKNK1 (0.76) | CYP11B1CYP11B2CYP19A1SLC2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010125402-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | CYP11B1 670/4885CYP11B2 780/4885CYP19A1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.